News

News Archive

Molecular Profiles to Launch US Strategic Alliance At AAPS Molecular Profiles to Launch US Strategic Alliance At AAPS

Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.

Sygnature Discovery Celebrates its 10th Birthday with a Symposium on Aspects of Modern Drug Discovery Sygnature Discovery Celebrates its 10th Birthday with a Symposium on Aspects of Modern Drug Discovery

Sygnature Discovery, the United Kingdom’s largest independent provider of integrated drug discovery resource and expertise, celebrated its 10th anniversary by hosting a symposium on “Aspects of Modern Drug Discovery”. Held at Nottingham’s East Midlands Conference Centre, the symposium welcomed distinguished scientific speakers from around the country to a packed audience of 200 guests.

New TSRI Studies Bring Scientists Closer to Combating Dangerous Unstable Proteins New TSRI Studies Bring Scientists Closer to Combating Dangerous Unstable Proteins

Scientists from The Scripps Research Institute (TSRI) have discovered new techniques to reduce protein deposits accumulating in key organs, causing a potentially deadly set of human diseases known as systemic amyloid diseases. Luke Wiseman, assistant professor at TSRI and a senior author of the new research, describes how a strategy to reduce the load coming from these proteins could open up treatment options that could be broadly applied to treat multiple systemic amyloid diseases.

£230 million for technologies to revolutionise research into disease £230 million for technologies to revolutionise research into disease

The Chancellor of the Exchequer, George Osborne, has today (Thursday 23 October) announced that a partnership led by the Medical Research Council (MRC) will invest over £230 million in a range of revolutionary technologies aimed at identifying the causes of diseases such as cancer and dementia, and dramatically speeding up diagnosis and treatment. The state-of-the-art technologies will be used to find out how differences in the cellular and molecular make-up of people affect how they respond to diseases and to treatment.

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

Domainex Ltd. and Auspherix Pty Ltd today announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate. Auspherix intends to develop much-needed new drugs to fight the increasing problem of antibiotic-resistant bacterial infections, which have been widely reported as one of the most significant threats to patients' safety across the world.*

The Current issue of “The view from here” discusses allosterism in drug discovery. The Current issue of “The view from here” discusses allosterism in drug discovery.

The topic of this month’s newsletter from Drug Discovery Today is allosterism in drug discovery.

Scripps Research Institute Scientists Link ALS Progression to Increased Protein Instability Scripps Research Institute Scientists Link ALS Progression to Increased Protein Instability

A new study by scientists from The Scripps Research Institute (TSRI), Lawrence Berkeley National Laboratory (Berkeley Lab) and other institutions suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Cancer Research Technology introduces Ximbio, an Online Reagents Portal Cancer Research Technology introduces Ximbio, an Online Reagents Portal

Ximbio aims to change the way reagents are searched, sourced and shared

Ambitious new studies will give new insights into Parkinson’s, addiction and the immune system Ambitious new studies will give new insights into Parkinson’s, addiction and the immune system

Three ambitious new research programmes, which aim to deliver a step-change in our understanding of disease by using human volunteers in experimental studies, have been funded as part of a £60m investment from the Medical Research Council (MRC).

Discovery helps to spot what makes a good drug Discovery helps to spot what makes a good drug

A new test developed by researchers from the University of Manchester could revolutionise the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available.